Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 41,076 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $28.70 on Friday. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -15.68 and a beta of 1.55. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $25.85 and a 200 day simple moving average of $25.04.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CNTA. Virtus Investment Advisers LLC raised its stake in shares of Centessa Pharmaceuticals by 6.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after acquiring an additional 583 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after purchasing an additional 870 shares during the last quarter. Coastal Bridge Advisors LLC boosted its position in Centessa Pharmaceuticals by 7.1% during the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of several research reports. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, B. Riley Financial boosted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus price target of $39.80.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.